Statement: past seven days frequency of ejaculation problems is a question about the frequency of an individual's ejaculation problems over the past seven days. neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications.
Primary_evidence: Outcome Measurement:    Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment   ORR is defined as the percentage of patients who exhibit a Complete Response (CR) or Partial Response (PR). Complete Response is the total disappearance of clinically and radiologically detectable disease for at least 4 weeks. Partial Response is at least a 50% reduction of all measurable lesions as measured by the product of the perpendicular diameters of the greatest dimensions of tumor size, with no new lesions appearing for at least four weeks.   Time frame: 18 Months Results 1:    Arm/Group Title: Arm A -Liposomal Doxorubicin Then Docetaxel   Arm/Group Description: Liposomal doxorubicin (Arm A)   Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle.   Patients demonstrating progression on Liposomal Doxorubicin were eligible for cross over to treatment on Docetaxel, provided the patient still met the eligibility laboratory and performance status criteria.   Overall Number of Participants Analyzed: 42   Measure Type: Number   Unit of Measure: percentage of patients  28        (16 to 42) Results 2:    Arm/Group Title: Arm B - Docetaxel Then Liposomal Doxorubicin   Arm/Group Description: Weekly docetaxel 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by one week rest, administered on a q 28 day cycle. This dosing schedule will define one cycle.   Patients demonstrating progression on Docetaxel were eligible for cross over to treatment on Liposomal Doxorubicin, provided the patient still met the eligibility laboratory and performance status criteria.   Overall Number of Participants Analyzed: 44   Measure Type: Number   Unit of Measure: percentage of patients  31        (18 to 45)